Vertex Pharmaceuticals has agreed to buy Crinetics Pharmaceuticals for $85.00 a share in cash — about $10 billion in equity value, or roughly $8.8 billion net of the cash on Crinetics’ books. Both boards approved the deal unanimously, and the companies expect it to close in the third quarter of 2026. Vertex will fund it with cash on hand and debt, backed by $4.5 billion of committed bridge financing from Bank of America and Morgan Stanley. At $85, the offer is more than double where Crinetics traded Monday — a premium of about 102% — and the stock jumped nearly 100% after hours. It is the largest acquisition in Vertex’s history.
The prize is a business that already sells something. Crinetics’ lead drug, Palsonify, won FDA approval in September 2025 as a once-daily oral pill for acromegaly, a rare disorder driven by excess growth hormone, and its early launch has shown real demand. Behind it sits atumelnant, another once-daily pill now in Phase 3 testing for congenital adrenal hyperplasia. Vertex pegs the combined endocrinology franchise at more than $5 billion in eventual annual revenue and expects the deal to start adding to non-GAAP operating income by 2029. In biotech terms, that is an unusually de-risked target: an approved, revenue-generating drug plus a late-stage follow-on, not a science experiment.
The premium is the tell. Vertex has spent more than a decade printing money from cystic fibrosis, where its Trikafta franchise dominates the disease — and just as long trying to prove it can win somewhere else. Newer bets in non-opioid pain relief and gene therapy haven’t yet silenced the question investors keep asking: what is the second act? Paying up for an already-approved endocrinology franchise answers it with cash instead of years of trial risk, and lets Vertex aim a rare-disease sales machine built for CF at a brand-new set of specialists. Biotech dealmaking has been heating up all year; this is the boldest swing so far.
Our take: Vertex didn’t pay a 100% premium because Crinetics was cheap. It paid because certainty is expensive. The whole logic here is buying a drug that is already approved and already selling — which strips out the coin flip that kills most biotech bets: the clinical trial. That is the same instinct now reshaping other industries — when growth is hard to build, big balance sheets buy it. The risk isn’t the science; it’s the price. At $10 billion for a franchise that won’t be accretive until 2029, Vertex is betting its commercialization muscle travels from lungs to endocrine glands. If Palsonify’s launch keeps climbing, it’s a steal. If it stalls, it’s the most expensive way yet to change the subject from cystic fibrosis.
What to watch
- Palsonify’s ramp: the deal math rests on the acromegaly launch accelerating. Watch quarterly prescription and reimbursement trends — that is the number Vertex is really buying.
- Atumelnant’s Phase 3: a win in congenital adrenal hyperplasia validates the “franchise, not one drug” thesis; a miss leaves Vertex leaning on a single product.
- The financing: $4.5 billion of bridge debt for a company used to running with net cash. Watch how much becomes permanent leverage on the same debt markets everyone is tapping.
- The M&A wave: a $10 billion deal at a roughly 100% premium, struck as patent cliffs loom across Big Pharma, could pull more buyers off the sidelines.